This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Exploring Systemic Nasal Delivery: Systems & Formulations
Publications, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation, Market Insights
Delivery of Biologics to the Nasal Cavity: The Future of Nasal Drug Delivery
Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations
Moving Towards Greater Recyclability in Drug Delivery – Sustainable Solutions b...
Webinars, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
Nasal Delivery of Biologics: A Whole New Ball Game
Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
